To estimate the age distribution of disease-causal HPV infection in women diagnosed with CIN2+ in England, highlighting its significance for public health.
Key Findings:
The model predicts the age distribution of causal HPV infection leading to CIN2+, with implications for public health strategies.
Approximately 8% of CIN2+ cases occurred before the age of screening (25 years), indicating a need for earlier intervention.
The model does not account for the impact of HPV vaccination introduced in 2008, which may affect incidence rates.
Interpretation:
Understanding the age of disease-causal HPV infection can inform HPV vaccination policies and screening strategies to reduce the burden of cervical precancer and cancer, emphasizing the need for targeted interventions.
Limitations:
The model does not incorporate the impact of HPV vaccination, which may skew results.
Excludes cases diagnosed at <25 years, potentially underestimating the incidence and introducing bias.
Conclusion:
The study provides insights into the timing of HPV infection acquisition related to CIN2+, which can guide public health strategies, particularly in vaccination and screening.
Updated guidelines position patient-collected testing as an option for patients aged 30 to 65 years who are at average risk of cervical cancer, with mandatory insurance coverage beginning January 2027
